We are live on ! Find out more
IRD

Opus Genetics
IRD

27 hedge funds and large institutions have $5.27M invested in Opus Genetics in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,300% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 1

93% more funds holding

Funds holding: 14 → 27 (+13)

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

12.04% less ownership

Funds ownership: 20.38% → 8.35% (-12%)

64% less capital invested

Capital invested by funds: $14.5M → $5.27M (-$9.2M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
27
Holders Change
+13
Holders Change %
+92.86%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
14
Increased
4
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$1.11M
2
NPF
Norris Perne & French
Michigan
+$733K
3
PVI
Pura Vida Investments
New York
+$535K
4
Renaissance Technologies
Renaissance Technologies
New York
+$370K
5
BFM
Boothbay Fund Management
New York
+$124K

Top Sellers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
-$15.5M
2
Squarepoint
Squarepoint
New York
-$85.5K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$5.53K
4
APA
American Portfolios Advisors
New York
-$13

IRD Hedge Fund Activity: Q1 2021 in Review

27 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q1 2021, worth a combined $5.27M — down 64% from $14.5M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IRD positions and 1 closed out — a net gain of 13 holders — while 4 added to existing stakes and 3 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.11M. The largest seller was Altium Capital Management, cutting an estimated $15.5M.

  • 27 institutional investors held Opus Genetics (IRD) as of Q1 2021, up from 14 in Q4 2020.
  • Funds reported $5.27M of Opus Genetics stock for Q1 2021, down 64% quarter-over-quarter.
  • 14 funds opened new Opus Genetics positions in Q1 2021 and 1 closed out, a net change of +13 holders.
  • The largest Opus Genetics buyer in Q1 2021 was Ikarian Capital, an estimated $1.11M added.
  • The largest Opus Genetics seller in Q1 2021 was Altium Capital Management, an estimated $15.5M sold.

Based on aggregated 13F filings for Q1 2021.